

Sachs Associates in association with Bloomberg L.P.

5TH ANNUAL BIOTECH IN EUROPE INVESTOR FORUM

4 - 5 October 2005, Swissôtel, Zurich

AGENDA, TUESDAY 4TH OCTOBER			
8.00	Registration		
	<u>BALLROOM:</u>		
8.50 - 9.20	<p>Chairman's Opening Welcome: Biotech start-up strategies in retrospect and outlook Dr. Rudolf Gygax, Managing Director, Novartis Venture Fund, Novartis International</p>		
9.20 - 9.40	<p>Keynote Presentation: Identifying the Symmetry between the European and US Market Dennis Purcell, Senior Managing Director, Perseus-Soros BioPharmaceutical Fund</p>		
9.40 - 10.25	<p>Panel Discussion: Global Investment Themes 2006 and beyond</p> <p>Chair: Dr. Jesper Zeuthen, Managing Director, BankInvest Biomedical Venture</p> <p>Panellists: Dr. Denise Pollard-Knight, Head of Nomura Phase4 Ventures, Nomura Phase4 Ventures Dr. Alexandra Goll, General Partner, Techno Venture Management (TVM) Dr. Andreas Wicki, Chief Executive Officer, HBM Partners Joël Besse, Senior Partner, Atlas Venture</p>		
10.25	Coffee Break		
11.05 - 13.10	Small-Cap Listed Company Presentations		
11.05	<p>ROOM ZURICH: Chair: Stan Yakatan, Katan Associates</p>	<p>ROOM BASEL: Chair: Dr. Kai Bindseil, BioTop</p>	<p>ROOM BERN: Chair: Dr Ivica _erina, NGN Capital</p>
11.10	<p>SyntheMed Robert Hickey, President & CEO</p>	<p>Biophan Technologies Michael Weiner, Chief Executive Officer</p>	<p>Cyberkinetics Neurotechnology Systems Tim Surgenor, President & CEO</p>
11.25	<p>Favrille Dr. John Longenecker, President & CEO</p>	<p>Acrux Dr. Igor Gonda, Managing Director & CEO</p>	<p>Clearant Alain Delongchamp, Chief Executive Officer</p>
11.40	<p>XL TechGroup Dr. John Scott, Chief Executive Officer</p>	<p>YM Biosciences David Allan, Chairman & CEO</p>	<p>Futura Medical James Barder, Chief Executive Officer</p>

11.55	CogState Dr. Peter Bick, Director & CEO	Evolutec Dr. Mark Carnegie Brown, Chief Executive Officer	Novadaq Technologies Dr. Arun Menawat, President & CEO
12.10	Generex Biotechnology Dr Gerald Bernstein, Vice President, Medical Affairs Director	Amarin Corporation Darren Cunningham, Executive Vice President, Strategic Development	Biotie Therapies Dr. Timo Veromaa, President & CEO
12.25	Biopure Corporation Zafiris Zafirelis, President & CEO	Plethora Solutions Dr. Steven Powell, Chief Executive Officer	
12.40	Oncolytics Biotech Dr. Brad Thompson, President & CEO	BioMS Medical Dr. Kjell Stenberg, Director	Diamyd Medical Anders Essen-Moller, Chief Executive Officer
12.55		Transgene Philippe Archinard, Chief Executive Officer	Swiss Medica Raghu Kilambi, Chief Executive Officer
13.15	Lunch		
14.15 - 16.20	Sector Workshops: Venture Funded Early – Mid Stage Biotech Companies		
14.15	ROOM ZURICH: IMMUNOLOGY/ONCOLOGY Chair: Christoph Schuler, SWX Swiss Exchange	ROOM BASEL: THERAPEUTICS Chair: Dr. Denise Pollard-Knight, Nomura Phase4 Ventures	ROOM BERN: THERAPEUTICS Chair: Dr. Hans A Küpper, Global Life Science Ventures
14.20	immatics biotechnologies Joerg Scheidle, Managing Director & CFO	DIREVO Biotech Andreas Richter, Chief Financial Officer	Biovertis Dr. Erich Felber, Chief Executive Officer
14.35	ImVision Dr. Martin Steiner, Chief Executive Officer	Necura Pharmaceuticals Speaker tbc	ACE BioSciences Ingelise Saunders, Chief Executive Officer
14.50	Avidex James Noble, Chief Executive Officer	Kuros Biosurgery Didier Cowling, President & CEO	Bayhill Therapeutics Dr. Mark Schwartz, President & CEO
15.05	Chroma Therapeutics Ian Nicholson, Chief Executive Officer	Speedel Konrad P Wirz, Chief Financial Officer	Neuro3d Dr. Bertrand Lehuu, Vice President Business Development
15.20	Heidelberg Pharma Dr. Jan Schmidt-Brand, Chief Executive Officer	DeveloGen Dr. Guenther Karmann, Chief Executive Officer	Apoxis Dr. Jean-Pierre Rosat, Chief Executive Officer
15.35	Austrianova Thomas Fischer, Chief Financial Officer	Cellerix Eduardo Bravo, Chief Executive Officer	Polyphor Dr. Jean-Pierre Obrecht, Chief Executive Officer
15.50	ESBATEch Dominik Escher, Chief Executive Officer	Ablynx Dr. Simon Kerry, Director Business Development	PIERIS Proteolab Dr. Volker Lang, Vice President Corporate Development
16.05	Santaris Pharma Dr. Keith McCullagh, Chief Executive Officer	Ingenium Pharmaceuticals Michael Grau, Chief Financial Officer	Affibody Torben Jørgensen, Chief Executive Officer
16.20	Coffee Break		

BALLROOM:

16.50

Welcome by Mayor of Zurich: Dr. Elmar Ledergerber

16.55

-

17.15

Investing in Biotechnology, a change in Climate?

Dr. Peter Reinisch, Partner, **Global Life Science Ventures**

Global Investor Roundtable

Chair:

Stan Yakatan, Chairman, **Katan Associates**

17.15

-

18.00

Panellists:

Dr. Brian Hargreaves Global Sector Head – Healthcare, **3i Group**

Dr. Yvonne Wegmann, Vice President, Head of Issuers & Investor

Relations, **SWX Swiss Exchange**

Antoine Papiernik, Managing Partner, **Sofinnova**

Nick Lowcock, Managing Director, **Warburg Pincus**

Dr. Hervé de Kergrohen, Partner, **CDC IXIS Innovation**

18.10

Cocktail Reception

Sachs Associates in association with Bloomberg L.P.

5TH ANNUAL BIOTECH IN EUROPE INVESTOR FORUM

4 - 5 October 2005, Swissôtel, Zurich

AGENDA, WEDNESDAY 5TH OCTOBER	
8.00	Registration
	<u>BALLROOM:</u>
9.00 - 9.15	Opening Welcome: Reviving the Biotech Industry Domenico Alexakis, Executive Director, Swiss Biotech Association
	Alliance Management: Avoiding the pitfalls. Strategic and Operational Best Practice Partnerships
9.15 - 10.00	Chair: Anthony Rosenberg, Global Head Business Development & Licensing, Novartis Pharma Panellists: Michael Levy, Vice President, Alliance Management, Bristol Myers Squibb Dr. Frank Grams, Global Alliance Director, F. Hoffman-La Roche Ltd Guy Eiferman, Vice President Alliance Management, Merck & Co Dr. Arnoud Dijkstra, Director Business Development, Actelion Pharmaceuticals
	Pharma – Biotech M&A; The interface between Big Pharma and Biotech on making a deal and the role investors play
10.00 - 10.50	Chair: Dimitri F Dimitriou M.Sc., Chief Executive Officer, DyoDelta Biosciences Ltd Panellists: Stephanie Léouzon, Managing Director, European Healthcare, Credit Suisse First Boston Sandrine Cailleteau, Head, Business Development & Licensing, Laboratoires Fournier Dr. Giancarlo Mennella, Managing Director, Egamid Dr. Carles Domenech, Director, Business Development, Lacer Dr Peter Johann, Managing General Partner, NGN Capital
10.50 - 11.20	Coffee Break

11.20 - 13.10	Sector Workshops: Venture Funded Early – Mid Stage Biotech Companies		
11.20	ROOM ZURICH: IMMUNOLOGY/ONCOLOGY Chair: Dr. Peter Kalinka, Accelsiors Group	ROOM BASEL: THERAPEUTICS Chair: Emma Palmer, Northbank Communications	ROOM BERN: THERAPEUTICS Chair: Dr. Morris Berrie, TechInvest
11.25	Intercell Alexander von Gabain, Chief Executive Officer	Archemix Dr. Errol De Souza, President & CEO	Artimplant Tord Lendau, Chief Executive Officer
11.40	BioVex Dr. Gareth Beynon, Chief Executive Officer	Scil Technology Dr. Irina Staatz-Granzer, Managing Director	IntegraGen Dr. Jan Mous, President & CEO
11.55	BOREAN PHARMA Dr. Johanna Holldack, Chief Executive Officer	mondoBIOTECH Prof. Dorian Bevec, Chief Scientific Officer	Xantos Biomedicine Stephan Wehselau, Chief Executive Officer
12.10	mtm laboratories Dr. Peter Pack, Founding member & CEO	Santhera Pharmaceuticals Barbara Heller, Chief Financial Officer	Biobase Michael Tysiak, Chief Executive Officer
12.25	Diatos Dr. John Tchelingierian, President & CEO	Amsterdam Molecular Therapeutics Prof. Sander van Deventer, Chief Scientific Officer & Dr. Ronald Lorijn, Chief Executive Officer	Sidec Technologies Hans Johansson, Chief Executive Officer
12.40	Nuevolution Alex Haahr Goulliaev, Chief Executive Officer	BioXell Dr. Francisco Sinigaglia, Chief Executive Officer	SweTree Technologies Mats Johnson, Chief Executive Officer
12.55	Merrimack Pharmaceuticals Robert Mulroy, President & CEO	PAD Pharma Stuart Wilson, Scientific Director	MNLpharma Hadyn Parry, Chief Executive Officer
13.15	Lunch		
14.15 - 15.00	2006 and beyond. Innovation and Investment in Medical Devices and Healthcare Technology in Switzerland		
	Chair: Christof Lenz, Siemens Medical Solutions		
	Panellists: Heinrich Christen, Partner, Ernst & Young Dr. Tom Geimer, Venture Partner, Heidelberg Innovation Stephan Meier, Partner, BB Medtech Christopher Meyer, Head of Business Development and Strategic Planning Medtronic Europe		
15.10	Close of Conference		